The FDA has tentatively approved Biocon Arm's Parkinson's medication capsules. Carbidopa-levodopa

The company's four strengths—23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg—are all covered by the approval. Parkinson's disease, post-encephalitic Parkinsonism, and Parkinsonism that may result from carbon monoxide or manganese overdose can all be treated with carbidopa and levodopa extended-release capsules, according to Biocon.